Search Results - "Danielewicz, Iwona"

Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial by Tomczak, Piotr, Venugopal, Balaji, Ferguson, Thomas, Chang, Yen-Hwa, Gross-Goupil, Marine, Burgents, Joseph E, Xu, Lei, Imai, Kentaro, Choueiri, Toni K, Venugopal, Balaji, Lin, Tzu-Ping, Symeonides, Stefan N., Sawrycki, Piotr, Haas, Naomi B., Sarwar, Naveed, Thiery-Vuillemin, Antoine, Gross-Goupil, Marine, Doshi, Gurjyot, Melichar, Bohuslav, Kopyltsov, Evgeniy, Hammers, Hans-Joerg, Menezes, Juliana de Janoski, Winquist, Eric W., Hamzaj, Alketa, Karaszewska, Boguslawa, Lipatov, Oleg N., McDermott, David, Kochuparambil, Samith T., Davis, Ian D., Peltola, Katriina, Sabbatini, Roberto, Shkolnik, Michail I., McCune, Steven, Yeung, Carrie, Laguerre, Brigitte, Fomin, Eugeniy A., Zakharia, Yousef, Yorio, Jeffrey T., Yanez Ruiz, Eduardo, Kimura, Go, Nishimura, Kazuo, Masumori, Naoya, Kato, Haruaki, Sala Gonzalez, Nuria, Chiu, Kun-Yuan, Atkins, Michael B., Heath, Elisabeth, Feyerabend, Susan, Numakura, Kazuyuki, Zukov, Ruslan, Maroto Rey, Pablo Jose, Chang, Chao-Hsiang, Vengalil, Salil, Waddell, Tom S., Hauke, Ralph, Jayram, Gautam, Estay, Angela, Rubiano, Juan Andres, Anai, Satoshi, Tsunemori, Hiroyuki, Sikora-Kupis, Bozena, Gunderson, Elizabeth, Koletsky, Alan, Chen, Kevin, Agrawal, Manish, Parnis, Francis, Barbosa, Fernando Maciel, Faucher, Genevieve, Iqbal, Nayyer, Hanna, Nawar, Ibanez, Carolina, Manneh, Ray, Holeckova, Petra, Ronkainen, Hanna, Abadie-Lacourtoisie, Sophie, Goebell, Peter J., Hoefner, Thomas, Schultze-Seemann, Wolfgang, Yokomizo, Akira, Matsukawa, Yoshihisa, Murakami, Yoji, Kim, Miso, Szczylik, Cezary, Humphreys, Alison C., Kumar, Birendra, Karam, Jose Antonio, Fleming, Mark, Zarba, Juan Jose, Leiva, Viviana E., Antonio Junior, Joao Neif, Rocha, Roberto Odebrecht, Muniz, David, Brust, Leandro, Graham, Jeffrey, Borchiellini, Delphine, McDermott, Ray, Miura, Yuji, Prow, Debra M., Hashemi-Sadraei, Neda, Kendall, Stephan D.

“…The first interim analysis of the KEYNOTE-564 study showed improved disease-free survival with adjuvant pembrolizumab compared with placebo after surgery in…”
Get full text

Knowledge and awareness of cervical cancer and prevention measures among female students in Poland: a cross-sectional, decade apart study by Wojewoda, Bartosz, Korman, Michał, Kamzol, Wojciech, Jaglarz-Biały, Katarzyna, Danielewicz, Iwona, Ziobro, Marek, Püsküllüoğlu, Mirosława

Get full text

In vivo treatment sensitivity testing with positron emission tomography/computed tomography after one cycle of chemotherapy for Hodgkin lymphoma by Hutchings, Martin, Kostakoglu, Lale, Zaucha, Jan Maciej, Malkowski, Bogdan, Biggi, Alberto, Danielewicz, Iwona, Loft, Annika, Specht, Lena, Lamonica, Dominick, Czuczman, Myron S, Nanni, Christina, Zinzani, Pier Luigi, Diehl, Louis, Stern, Richard, Coleman, Morton

“…Negative [(18)F]fluorodeoxyglucose (FDG) -positron emission tomography (PET)/computed tomography (CT) after two cycles of chemotherapy indicates a favorable…”
Get full text

Radium-223 in women with hormone receptor-positive bone-metastatic breast cancer receiving endocrine therapy: pooled analysis of two international, phase 2, randomized, double-blind, placebo-controlled trials by Rugo, Hope S., Van Poznak, Catherine H., Neven, Patrick, Danielewicz, Iwona, Lee, Soo Chin, Campone, Mario, Chik, Jeannie Y. K., Vega Alonso, Estela, Naume, Bjørn, Brain, Etienne, Siegel, Jonathan M., Li, Rui, Uema, Deise, Wagner, Volker J., Coleman, Robert E.

“…Background Most women with advanced breast cancer have skeletal metastases. Radium-223 is an alpha-emitting radionuclide that selectively targets areas of bone…”
Get full text

RESILIENT Part 2: A Randomized, Open-Label Phase III Study of Liposomal Irinotecan Versus Topotecan in Adults With Relapsed Small Cell Lung Cancer by Spigel, David R, Dowlati, Afshin, Chen, Yuanbin, Navarro, Alejandro, Yang, James Chih-Hsin, Stojanovic, Goran, Jove, Maria, Rich, Patricia, Andric, Zoran G, Wu, Yi-Long, Rudin, Charles M, Chen, Huanyu, Zhang, Li, Yeung, Stanley, Benzaghou, Fawzi, Paz-Ares, Luis, Bunn, Paul A

“…The phase III RESILIENT trial compared second-line liposomal irinotecan with topotecan in patients with small cell lung cancer (SCLC). Patients with SCLC and…”
Get full text

Phase II study evaluating trifluridine/tipiracil + bevacizumab and capecitabine + bevacizumab in first-line unresectable metastatic colorectal cancer (mCRC) patients who are noneligible for intensive therapy (TASCO1): Results of the final analysis on the overall survival by Van Cutsem, Eric, Danielewicz, Iwona, Saunders, Mark P., Pfeiffer, Per, Argiles, Guillem, Borg, Christophe, Glynne-Jones, Robert, Punt, Cornelis J. A., van de Wouw, Agnes J., Fedyanin, Mikhail, Stroyakovskiy, Daniil, Kroening, Hendrik, Garcia-Alfonso, Pilar, Wasan, Harpreet Singh, Falcone, Alfredo, Aubel, Paul, Egorov, Anton, Amellal, Nadia, Moiseenko, Vladimir

“…Abstract only 14 Background: Our phase II randomized study was conducted in patients with previously untreated unresectable mCRC not eligible to receive…”
Get full text

Phase 3 SELENE study: ibrutinib plus BR/R-CHOP in previously treated patients with follicular or marginal zone lymphoma by Nastoupil, Loretta J., Hess, Georg, Pavlovsky, Miguel A., Danielewicz, Iwona, Freeman, Jane, García-Sancho, Alejandro Martin, Glazunova, Valeria, Grigg, Andrew, Hou, Jing-Zhou, Janssens, Ann, Kim, Seok Jin, Masliak, Zvenyslava, McKay, Pam, Merli, Francesco, Munakata, Wataru, Nagai, Hirokazu, Özcan, Muhit, Preis, Meir, Wang, Tingyu, Rowe, Melissa, Tamegnon, Monelle, Qin, Rui, Henninger, Todd, Curtis, Madeliene, Caces, Donne Bennett, Thieblemont, Catherine, Salles, Gilles

“…•SELENE is a phase 3, placebo-controlled trial evaluating ibrutinib or placebo added to BR/R-CHOP for patients with R/R FL or MZL.•The addition of ibrutinib to…”
Get full text

Early treatment intensification with escalated BEACOPP in patients with Hodgkins lymphoma not responding to ABVD therapy by Danielewicz, Iwona, Małkowski, Bogdan, Zaucha, Renata, Zalewska, Marta, Leśniewski-Kmak, Krzysztof, Zaucha, Jan Maciej

Get more information

The role of PET for interim response assessment in patients with Hodgkin's lymphoma by Zaucha, Jan, Danielewicz, Iwona, Malkowski, Bogdan, Zaucha, Renata, Lesniewski-Kmak, Krzysztof

“…18F 2-fluoro-2-deoxyglucose positron emission tomography (FDG-PET) assessment after completion of therapy for lymphomas has been recently incorporated into the…”
Get full text